In recent months, the contract manufacturing market has seen a wave of investment in the U.S. amid the COVID-19 pandemic and a call for “onshore” drug production. Now, Baxter’s CDMO arm is stepping up to the plate with a finishing technology expansion at its Indiana site.
Baxter Biopharma Solutions, the CDMO arm of healthcare giant Baxter, will shell out $50 million in an expansion to its fill-finish manufacturing plant in Bloomington, Indiana, that will eventually bring 100 new positions on board, the company said Tuesday.
The expansion will add a 25,000-square-foot warehouse; a new filling line for flexible plastic containers; a high-speed automated syringe fill line capable of filling up to 600 units per minute; and a new high-speed, automated visual inspection line, Baxter said.
Construction has already begun and is expected to be completed in 2021, Baxter said. The CDMO will then begin taking on contracts in 2022.
The Bloomington site handles clinical and commercial manufacturing for drugs from roughly 25 biopharma companies, Baxter said in a release.
Baxter and its CDMO arm have had a relatively quiet past few years for a multibillion-dollar global enterprise.
Back in 2016, the firm agreed to buy sterile injectables specialist Claris Lifesciences for $625 million, which added three manufacturing facilities, 11 drugs approved in the U.S. and a pipeline of other products. Baxter said the addition of the Indian drugmaker would allow the combined company to launch seven to nine new products a year in the short term and up to 15 products a year after 2019.
In early 2017, the company settled federal claims that it distributed “adulterated” sterile injectables products from a legacy manufacturing site plagued by mold and paid $16 million in penalties and forfeiture as part of a deferred prosecution agreement. It also agreed to regularly report on improvements made to its manufacturing operations.
by Kyle Blankenship
Source: fiercepharma.com
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.
